Fact sheet: Franklin Biotech Disc

Fund information
Fund name
Franklin Biotechnology Discovery A Acc USD
Fund manager company
Franklin Temp Intnl Serv SARL
Fund type
Offshore Fund
Fund managers
  • Evan McCullochsince 01/11/2000
  • Christopher Jay Leesince 30/04/2016
  • Steve Kornfeldsince 14/09/2015
Fund objective
The Fund aims to achieve capital appreciation by investing principally in equity securities of biotechnology companies and discovery research firms mainly located in the US.
Benchmark
  • NASDAQ Biotechnology
Investment style
Growth
Investment method
Shares
Quick stats
1 Year return
-10.1%
1 Year rank in sector
15/31
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
1.81%
Fund size
£2,034m (£2,666m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
216
Top in this sector
Fund name1 Year
Pictet Health6.3%
Fidelity Gbl Health Care4.2%
BB Medtech3.7%
Variopartner SICAV MVGbMdtcF2.9%
Wellington GlHthcr LS-0.9%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • USA90.6%
    Money Market4.8%
    UK1.5%
    Netherlands0.9%
    Canada0.7%
  • Equities95.2%
    Cash & Cash Equivalents4.8%
  • US Equities95.2%
    Money Market4.8%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund7.9%0.6%3.7%-10.1%25.8%156.7%
Sector3%-4.7%-2.5%-8.8%25.5%109.2%
Rank within sector3 / 322 / 324 / 3215 / 3114 / 267 / 24
Quartile1st1st1st2nd3rd2nd
Calendar performance
 YTD - 20162015201420132012
Fund-14%4.9%34.7%64.3%26.8%
Sector-10.1%7.2%28.1%41%16.7%
Rank within sector22 / 3122 / 2915 / 262 / 246 / 24
Quartile3rd4th3rd1st1st
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
-3.31
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
1.53
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.15
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
27.06
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
13.94
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
-0.06
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.85
Price movement
52 week high33.42
52 week low23.22
Current bid price-
Current offer price-
Current mid price27.58
Region
1USA90.6%
2Money Market4.84%
3UK1.52%
4Netherlands0.85%
5Canada0.66%
6Israel0.65%
7Switzerland0.4%
8Cayman Islands0.29%
9France0.13%
Industry sector
1Equities95.16%
2Cash & Cash Equivalents4.84%
Asset type
1US Equities95.16%
2Money Market4.84%
Individual holdings
1CELGENE CORP9.64%
2BIOGEN INC7.91%
3TESARO INC7.35%
4GILEAD SCIENCES INC7.3%
5INCYTE CORP4.68%
6AMGEN INC4.38%
7REGENERON PHARMACEUTICALS INC3.06%
8VERTEX PHARMACEUTICAL2.98%
9ALEXION PHARMACEUTICALS INC2.84%
Management
Fund manager group
Franklin Templeton
Fund manager company
Franklin Temp Intnl Serv SARL
Fund type
Offshore Fund
Fund objective
The Fund aims to achieve capital appreciation by investing principally in equity securities of biotechnology companies and discovery research firms mainly located in the US.
Benchmark
  • NASDAQ Biotechnology
Investment style
Growth
Investment method
Shares
Fund managers
NameSinceBiography
Evan McCulloch01/11/2000Evan McCulloch is a vice president, portfolio manager and analyst for Franklin Equity Group. Mr. McCulloch is the lead portfolio manager of Franklin Biotechnology Discovery Fund. He is also the health care sector team leader. Mr. McCulloch specialises in research analysis of biotechnology and emerging pharmaceutical companies, with a therapeutic focus on infectious diseases, ophthalmology, pulmonology, cardiovascular disease, gastroenterology and the central nervous system. Prior research coverage includes the pharmaceutical, medical technology and healthcare service sectors. Mr. McCulloch joined Franklin Templeton Investments in 1992. He earned his B.A. in economics from the University of California at Berkeley. He is a Chartered Financial Analyst (CFA) Charterholder, and a member of the CFA Institute and the Security Analysts of San Francisco (SASF).
Christopher Jay Lee30/04/2016
Steve Kornfeld14/09/2015Steven Kornfeld is a vice president, research analyst and portfolio manager with Franklin Equity Group. He specializes in research analysis of the pharmaceutical industry and is a member of the Franklin Core Equity management team. He manages several portfolios including Franklin Focused Core Equity Fund.Prior to joining Franklin Templeton Investments in January 2001, Mr. Kornfeld most recently worked in private equity and previously as a sell-side research analyst where he specialized in covering emerging growth companies.Mr. Kornfeld holds an M.B.A. from Northwestern University's Kellogg Graduate School of Management and a bachelor's degree from the Wharton School of Business at the University of Pennsylvania. He is a Charted Financial Analyst (CFA) Charterholder.
Compliance
Transparent for Austrian Tax, Transparent for Swiss Tax, CPF Ordinary, Reporting Fund Status, SRS, UCITS V Compliant, MAS Unrestricted Scheme
Domicile
No data available.
Fund for sale in
Austria, Belgium, Switzerland, Cyprus, Czech Republic, Germany, Denmark, Spain, Estonia, Finland, France, United Kingdom, Gibraltar, Greece, Guernsey, Hong Kong, Hungary, Ireland, Italy, Jersey, Republic Of Korea, Lithuania, Luxembourg, Latvia, Macau, Netherlands, Norway, Offshore, Peru, Poland, Portugal, Singapore, Slovakia, Sweden, Taiwan - Province Of China, South Africa
Franklin Biotechnology Discovery A Acc HKD
Initial charge5.75%
Annual charge1%
Min single investment£5,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)1.8%
Total expense ratio (TER)1.81%
Bid price-
Offer price-
Mid price17.83
CurrencyHKD
Price updated07/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeF68H
Franklin Biotechnology Discovery A Acc SGD
Initial charge5.75%
Annual charge1%
Min single investment£5,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)1.81%
Total expense ratio (TER)1.81%
Bid price-
Offer price-
Mid price28.49
CurrencySGD
Price updated07/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeBDO3
Franklin Biotechnology Discovery A Acc USD
Initial charge5.75%
Annual charge1%
Min single investment£5,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)1.81%
Total expense ratio (TER)1.82%
Bid price-
Offer price-
Mid price27.58
CurrencyUSD
Price updated07/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeUJ87
Franklin Biotechnology Discovery A H1 Acc CHF
Initial charge5.75%
Annual charge1%
Min single investment£5,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)1.8%
Total expense ratio (TER)1.81%
Bid price-
Offer price-
Mid price13.62
CurrencyCHF
Price updated07/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFBCJ
Franklin Biotechnology Discovery B Acc USD
Initial charge-
Annual charge1%
Min single investment£5,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)3.12%
Total expense ratio (TER)3.13%
Bid price-
Offer price-
Mid price22.3
CurrencyUSD
Price updated07/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeUJ88
Franklin Biotechnology Discovery C Acc USD
Initial charge-
Annual charge1%
Min single investment£5,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)2.39%
Total expense ratio (TER)2.39%
Bid price-
Offer price-
Mid price32.88
CurrencyUSD
Price updated07/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeW927
Franklin Biotechnology Discovery I Acc USD
Initial charge-
Annual charge0.7%
Min single investment£5,000,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)0.96%
Total expense ratio (TER)0.97%
Bid price-
Offer price-
Mid price41.14
CurrencyUSD
Price updated07/12/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeF143
Franklin Biotechnology Discovery I H1 Acc EUR
Initial charge-
Annual charge0.7%
Min single investment£5,000,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)0.97%
Total expense ratio (TER)0.96%
Bid price-
Offer price-
Mid price18.45
CurrencyEUR
Price updated07/12/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeF68I
Franklin Biotechnology Discovery N Acc USD
Initial charge3%
Annual charge1%
Min single investment£5,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)2.56%
Total expense ratio (TER)2.56%
Bid price-
Offer price-
Mid price24.14
CurrencyUSD
Price updated07/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFN42
Franklin Biotechnology Discovery W Acc USD
Initial charge-
Annual charge0.75%
Min single investment£3,000,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)1.06%
Total expense ratio (TER)1.04%
Bid price-
Offer price-
Mid price12.91
CurrencyUSD
Price updated07/12/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeFDQE
Franklin Biotechnology Discovery Z Acc GBP
Initial charge-
Annual charge1%
Min single investment£5,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)1.31%
Total expense ratio (TER)1.31%
Bid price-
Offer price-
Mid price28.44
CurrencyGBP
Price updated07/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi code139O
Franklin Biotechnology Discovery Z Acc USD
Initial charge-
Annual charge1%
Min single investment£5,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)1.36%
Total expense ratio (TER)1.25%
Bid price-
Offer price-
Mid price9.92
CurrencyUSD
Price updated07/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeEANL
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.